CLINICAL CASE-BASED LEARNING MODULE

Comprehensive Pharmacologic
Management of
Type 2 Diabetes Mellitus
A Clinical Decision-Making Module
─────────────────────────────────
PART 1: Foundation of Clinical Approach Before Starting Pharmacologic
Therapy
─────────────────────────────────
Target Audience: Medical Doctors, Residents & Advanced Medical Trainees
Aligned with ADA Standards of Care & International Evidence-Based Guidelines
 HOW TO USE THIS MODULE
This module is designed as a bedside handbook and exam preparation resource.
• Each section builds logically — complete Part 1 before proceeding to Parts 2–4.
• Tables are designed for rapid clinical reference during patient encounters.
• Clinical Pearls highlight practical bedside points not always found in textbooks.
• Exam Pearls flag high-yield facts commonly tested in postgraduate examinations.
• Cases in Parts 2–4 demonstrate real-world application of concepts from Part 1.
• Part 1 = Foundation → Part 2 = Drug Classes → Part 3 = Complex Cases → Part 4 =
Special Populations & Monitoring

SECTION 1: Clinical Approach to Newly Diagnosed Type 2

Diabetes Mellitus

The first clinical encounter with a newly diagnosed diabetic patient is the most impactful. It sets the framework for
treatment, targets, patient education, and long-term monitoring. A systematic, unhurried approach at this visit
prevents misclassification, missed comorbidities, and inappropriate therapy.

1.1 Confirming the Diagnosis

Diagnostic Criteria (Any ONE criterion is sufficient if asymptomatic × 2; ONE if
symptomatic)

Diagnostic Test Threshold Value Clinical Notes

Fasting Plasma Glucose ≥ 126 mg/dL (7.0 mmol/L) Fasting ≥ 8 hours; repeat if
(FPG) asymptomatic

2-hour OGTT (75g) ≥ 200 mg/dL (11.1 mmol/L) Gold standard for borderline
cases

HbA1c ≥ 6.5% (48 mmol/mol) Avoid if hemoglobinopathy,

hemolysis, or pregnancy

Random Plasma Glucose ≥ 200 mg/dL (11.1 mmol/L) No confirmation needed if

+ Symptoms classic symptoms present

★ EXAM PEARL
EXAM PEARL: HbA1c is NOT reliable in hemolytic anemia, sickle cell disease, recent blood
transfusion, or pregnancy. Use FPG or OGTT in these situations.

◆ CLINICAL PEARL
CLINICAL PEARL: In a symptomatic patient with classic hyperglycemic symptoms (polyuria,
polydipsia, weight loss) and a random glucose ≥200 mg/dL — NO repeat test is needed. One
result is diagnostic.
1.2 Differentiating Type 2 DM from Other Forms
This distinction is critical because misclassification leads to inappropriate treatment. The most dangerous error is
labelling a LADA patient as Type 2 and underutilizing insulin.

Feature Type 2 DM Type 1 DM LADA Secondary

DM

Typical age Usually >35 yrs Usually <30 yrs 30–60 yrs Any age

Onset Gradual Rapid/acute Insidious Varies

Body habitus Usually obese Usually lean Usually lean Variable

Ketoacidosis risk Low (unless High Low initially Depends on

stress) cause

C-peptide Normal/high Very low/absent Declining Depends on

cause
Autoantibodies Negative Positive Positive (key!) Negative
(GAD, IA-2)

Initial insulin Usually not Always needed Needed within 5 Varies

response needed yrs

Family history Common Less common Sometimes May be absent

DM

◆ CLINICAL PEARL
CLINICAL PEARL — LADA Trap: A lean adult aged 30–55 who fails oral agents within 1–2 years
despite good adherence should prompt measurement of GAD antibodies and C-peptide. LADA is
frequently misclassified as T2DM.

Secondary Causes of Diabetes to Exclude at First Visit

• Cushing syndrome (central obesity, hypertension, easy bruising, striae)
• Acromegaly (jaw / hand / foot enlargement, sweating, hypertension)
• Glucagonoma (necrolytic migratory erythema, weight loss, diarrhea)
• Pheochromocytoma (episodic hypertension, headache, diaphoresis, palpitations)
• Hemochromatosis (bronze skin, liver disease, arthropathy, cardiac disease)
• Pancreatic disease: chronic pancreatitis, cystic fibrosis, pancreatic surgery
• Drug-induced: corticosteroids, atypical antipsychotics (clozapine, olanzapine), tacrolimus,
thiazides in high doses
Clinical tip: If secondary DM is suspected, treat the underlying cause first — glucose may
normalize.

1.3 Initial Clinical Assessment

The initial assessment must cover symptom burden, timeline of hyperglycemia, and presence of dangerous
features requiring urgent intervention.
Key Assessment Areas
• Symptom assessment: Ask specifically about polyuria, polydipsia, fatigue, blurred vision, genital infections,
and numbness/tingling
• Duration of hyperglycemia: Incidental diagnosis (asymptomatic, routine screen) vs. symptomatic for
weeks/months — the longer the duration, the higher the complication burden already present at diagnosis
• Severity of presentation: Is the patient well or ill? Can they be managed as an outpatient?
• Catabolic features: Unintentional weight loss, muscle wasting, ketonuria/ketonemia — these suggest insulin
deficiency and may warrant early insulin initiation or reconsideration of T2DM classification

⚠ CAUTION
If a newly diagnosed patient presents with marked weight loss, ketonuria, ketoacidosis, or rapid
deterioration despite oral therapy — suspect LADA or Type 1 DM. Initiate insulin urgently and
measure GAD antibodies and C-peptide.

1.4 Baseline Laboratory Evaluation

Investigation Purpose Action Threshold

HbA1c Confirm diagnosis; establish ≥6.5% confirms DM

baseline

FPG / OGTT Confirm diagnosis if HbA1c See diagnostic table above

unreliable

eGFR (CKD-EPI) Renal function; guides drug <60 = CKD; affects

choice metformin, SGLT2, drug
dosing

Urine ACR Early nephropathy screening >30 mg/g =

microalbuminuria → treat

Fasting lipid panel Assess ASCVD risk; guide statin LDL-C <70 if high ASCVD
therapy risk

Liver enzymes (ALT/AST) Baseline for ALT >2.5x ULN: use

metformin/pioglitazone safety alternatives

TSH Exclude thyroid as contributor Treat if abnormal

C-peptide + GAD antibodies Only if T1DM / LADA suspected Low C-pep + GAD+ = LADA
or T1DM

ECG (resting) Baseline CVD; silent MI in DM Refer if abnormal

patients

BP measurement Hypertension co-management >130/80 = treat in DM

Weight / BMI / Waist Obesity assessment; guides BMI >25 (or >23 in Asians)
circumference medication

Foot exam + ABI if indicated Peripheral vascular disease / Monofilament loss = high
neuropathy risk

Dilated fundoscopy Baseline retinopathy Refer to ophthalmology if

positive
 ★ EXAM PEARL
EXAM PEARL: In a patient with new T2DM + eGFR <30, metformin is CONTRAINDICATED due
to risk of lactic acidosis. Also, SGLT2 inhibitors provide minimal glycemic benefit below eGFR 45
(though still renally protective down to eGFR 20 in some guidelines).

1.5 First Visit Diabetes Assessment Checklist

Use this at every first encounter with a newly diagnosed (or newly referred) T2DM patient:

✓ First Visit Assessment Item Clinical Purpose / What to Look For

☐ Symptoms: polyuria, polydipsia, fatigue, blurred Distinguish acute decompensation vs

vision, weight loss incidental diagnosis

☐ Estimated duration of hyperglycemia Long undetected DM → higher complication

(symptomatic vs asymptomatic) burden

☐ Catabolic features: unintentional weight loss, If present → consider T1DM/LADA; may

ketonuria need early insulin

☐ Review all current medications (steroids, Drug-induced hyperglycemia must be

antipsychotics, thiazides) identified

☐ Family history of diabetes (type, treatment, Guides genetic risk; MODY suspicion if
complications) young + family history

☐ History of ASCVD: MI, stroke, PAD, coronary Drives medication selection (SGLT2i / GLP-
revascularization 1 RA preferred)

☐ Heart failure symptoms: dyspnea, orthopnea, Affects drug choice; avoid TZDs; prefer
edema SGLT2i

☐ CKD / urinary symptoms / foamy urine Affects metformin use; check eGFR and
ACR

☐ Hypertension, dyslipidemia, smoking: current Comprehensive CVD risk management

management

☐ Dietary habits, physical activity level, work Key for lifestyle counseling; affects glycemic
schedule pattern

☐ Hypoglycemia history: frequency, severity, Guides safe target setting and drug choice
awareness

☐ Alcohol use, liver disease history Affects metformin, GLP-1 RA, sulfonylurea
safety

☐ Pregnancy status or planning (women of Metformin is preferred oral; insulin may be

childbearing age) needed

☐ Cognitive function, frailty, fall risk (elderly Avoid hypoglycemia; set less stringent
patients) targets

☐ Cost constraints / insurance / medication Guide formulary-appropriate prescribing

access

☐ Social support / health literacy / cultural factors Key for self-management success
◆ CLINICAL PEARL
CLINICAL PEARL: The best 10 minutes at a first visit are spent understanding the patient's story
— not just ordering tests. Knowing a patient is a long-distance truck driver who cannot afford
hypoglycemia, or a recently unemployed patient who cannot afford insulin, changes every
prescribing decision.
SECTION 2: Assessment of Cardiovascular Risk and
Important Comorbidities

Drug selection in T2DM is no longer driven purely by glycemic efficacy. Modern guidelines mandate comorbidity-
driven drug selection — particularly for ASCVD, heart failure, and CKD — because these conditions determine
both prognosis and the choice of pharmacotherapy.

2A. Cardiovascular Risk and Key Comorbidities

Comorbidity How to Assess Drug Selection Implication

Established ASCVD (MI, History, ECG, ABI, imaging Prioritize GLP-1 RA or SGLT2i with
stroke, PAD) proven CV benefit
Heart Failure (HFrEF or Symptoms, Echo, BNP SGLT2i first-line; avoid TZDs
HFpEF) (worsen HF)

Chronic Kidney Disease eGFR, Urine ACR SGLT2i if eGFR ≥20; metformin if
eGFR ≥30; adjust all agents

Hypertension BP ≥130/80 mmHg in DM Co-manage with RAAS inhibitors;

SGLT2i has mild BP-lowering benefit

Dyslipidemia Fasting lipid panel Statin therapy in most T2DM; LDL-C

target driven by CV risk

Obesity (BMI ≥30 or ≥27 BMI, waist circumference Prefer weight-lowering agents: GLP-
+ complication) 1 RA, SGLT2i; avoid TZDs/SU if
possible

★ EXAM PEARL
EXAM PEARL: The presence of established ASCVD (prior MI, stroke, or PAD) is the most
powerful driver for choosing a GLP-1 RA or SGLT2i — regardless of HbA1c level. These drugs
reduce cardiovascular events independent of glucose lowering.

ASCVD Risk Stratification in T2DM — Practical Summary

Very High Risk (prioritize SGLT2i or GLP-1 RA with CV evidence):
• Established ASCVD: prior MI, ischemic stroke, PAD, coronary revascularization
• CKD with albuminuria (ACR >300 mg/g)
High Risk (consider CV-protective agents as second agent):
• Multiple major CV risk factors: age >50 + hypertension + smoking + dyslipidemia
• LVH, eGFR <60, microalbuminuria
Moderate Risk (standard therapy, focus on glycemic + risk factor control):
• Young T2DM patient with no additional CV risk factors
2B. Diabetes-Related Complications

Complication Initial Screening Implication for Drug Management

Retinopathy Dilated fundus exam at Rapid HbA1c lowering can transiently

diagnosis worsen retinopathy — avoid precipitous
drops

Nephropathy eGFR + Urine ACR Drive SGLT2i and RAAS inhibitor use;
dose-adjust or avoid some agents

Peripheral Monofilament, vibration, Avoid hypoglycemia (worsens

Neuropathy ankle reflexes neuropathic pain awareness)

Autonomic Orthostatic BP, Gastroparesis → caution with GLP-1 RA;

Neuropathy gastroparesis symptoms unpredictable drug absorption

Foot Disease / PAD ABI, foot inspection, pulses No specific drug change, but aggressive
CV risk reduction essential

NAFLD/NASH Liver enzymes, ultrasound Pioglitazone may benefit NASH; avoid in

heart failure

◆ CLINICAL PEARL
CLINICAL PEARL: Complications are not just targets for monitoring — they directly modify
prescribing. A patient with T2DM + CKD + microalbuminuria has two mandatory drug classes: an
SGLT2 inhibitor (for renal protection) AND a RAAS inhibitor (ACE inhibitor or ARB). These are
not optional extras.

2C. Drug Selection Modifying Factors — Full Checklist

Complete this mental checklist (or literal checklist) before prescribing any diabetes medication:

Modifying Factor Assessment Method Clinical Implication

Frailty / Functional Clinical Frailty Scale, Avoid hypoglycemia strictly; set HbA1c
decline ADLs <8.5%; simplify regimen

Older age (>75 years) Cognitive assessment, Avoid sulfonylureas, TZDs; deprescribe
falls history if needed; target HbA1c 7.5–8.5%

Hypoglycemia risk History, medication Avoid SU, insulin where possible; use
(history of severe review SGLT2i, GLP-1 RA, DPP4i
hypoglycemia)

Liver disease LFTs, history, Avoid metformin (lactic acidosis), SU

(cirrhosis/active hepatitis) ultrasound (hypoglycemia); caution with TZDs

Renal impairment (eGFR eGFR calculation Stop metformin if eGFR <30; dose-
<30–45) adjust DPP4i; SGLT2i less effective
<45

Pregnancy / planning Pregnancy test, Metformin + insulin are safe; stop GLP-
pregnancy contraceptive history 1 RA, SGLT2i, DPP4i

Occupational risk of Occupation history Strictly avoid hypoglycemia risk; prefer

 Modifying Factor Assessment Method Clinical Implication

hypoglycemia (drivers, agents with low hypoglycemia profile

pilots, machine operators)

Cost / access (low- Insurance, Metformin ± SU as backbone; prioritize

resource settings) socioeconomic history affordable formulations

Adherence challenges / Pill count, refill history Once-weekly GLP-1 RA; fixed-dose
polypharmacy burden combinations to reduce pill burden

Active cancer treatment / Oncology history, Steroid-induced hyperglycemia may

immunosuppression steroid use need insulin; GLP-1 RA generally safe

2D. Pre-Prescribing Modifying Factors Checklist

DRUG SELECTION MODIFYING FACTORS — Pre-Prescribing Checklist

▸ CARDIOVASCULAR
☐ Does patient have established ASCVD? → GLP-1 RA or SGLT2i with proven CV benefit
☐ Does patient have heart failure? → SGLT2i preferred; avoid TZDs
☐ 10-year ASCVD risk >10%? → Weight CV protective agents more heavily
▸ RENAL
☐ eGFR <30? → Stop metformin; avoid SGLT2i for glucose lowering; adjust DPP4i
☐ eGFR 30–44? → Reduce metformin dose; SGLT2i less effective
☐ Urine ACR >300 mg/g? → SGLT2i + RAAS inhibitor mandatory
▸ WEIGHT
☐ BMI ≥30? → Prefer GLP-1 RA (high weight loss) or SGLT2i
☐ Underweight or weight neutral goal? → DPP4i or metformin preferred
☐ Need to avoid weight gain? → Avoid TZDs and insulin where feasible
▸ HYPOGLYCEMIA RISK
☐ Elderly / frail? → Avoid sulfonylureas and complex insulin regimens
☐ Hypoglycemia unawareness history? → CGM consideration; avoid SU
☐ High-risk occupation? → Use only low-hypoglycemia-risk agents
▸ PATIENT-SPECIFIC
☐ Active pregnancy or planning? → Metformin + insulin; discontinue other agents
☐ Liver disease? → Avoid metformin (Child-Pugh C); avoid SU
☐ Cost-sensitive? → Metformin + SU + human insulin remain standard in LMIC
☐ Poor adherence predicted? → Once-weekly semaglutide; fixed-dose combinations

★ EXAM PEARL
EXAM PEARL: In resource-limited settings, the combination of Metformin + Sulfonylurea + Basal
Human Insulin (NPH) remains a valid, evidence-based regimen. It is NOT inferior to newer
agents in glycemic control — it only lacks proven CV/renal organ-protective benefits of SGLT2i
and GLP-1 RA.
SECTION 3: Individualized Glycemic Target Setting

One of the most critical — and most commonly neglected — aspects of diabetes management is matching the
glycemic target to the individual patient. Applying a uniform HbA1c <7% to every patient is not only unscientific
but potentially harmful.

3.1 Why Glycemic Targets Must Be Individualized

The argument for individualization rests on a core tension in diabetes medicine:
• Tight glycemic control (HbA1c <6.5–7%) → Best long-term microvascular protection
• But → increases hypoglycemia risk, especially with insulin and sulfonylureas
• And → hypoglycemia in vulnerable patients (elderly, CVD, frail) → arrhythmias, falls, cognitive impairment,
death
• Evidence: ACCORD trial showed that intensive control (HbA1c ~6.4%) increased mortality in high-risk
T2DM patients — establishing that 'tighter is not always safer'

3.2 Factors That Individualize the Target

Factor Tighter Target Favored Relaxed Target Favored
When... When...

Age Young patient, decades of life Elderly >75 yrs, especially if

ahead frail

Duration of DM Newly diagnosed (legacy Long-standing DM (>10–15

effect benefit) years), established
complications

Life expectancy Long life expectancy Short life expectancy (<5

years)

Comorbidities Healthy, no major organ Severe CVD, renal failure,

disease advanced malignancy
Hypoglycemia risk Using low-risk agents (GLP-1 On insulin + sulfonylurea;
RA, SGLT2i) hypoglycemia unawareness

Patient preference Highly motivated, compliant, Prefers simplicity; limited self-

self-monitoring care ability

Cognitive function Intact cognition Dementia, cognitive

impairment

Social support Good support, can recognize Lives alone, poor access to
hypoglycemia emergency care

3.3 Practical Glycemic Target Table by Patient Profile

 Patient Profile HbA1c Target Rationale / Key
Considerations

Young, newly diagnosed, long life < 6.5% Maximizes long-term benefit;
expectancy, no hypoglycemia risk, tight control early slows
motivated complications (legacy effect)

Most adults with T2DM, no < 7.0% Standard ADA target; balances
significant comorbidities benefit and risk

Significant hypoglycemia risk, < 7.5–8.0% Benefit-risk balance shifts; tight

moderate comorbidities, adherence control may be harmful
concerns

Elderly, frail, limited life expectancy, < 8.0–8.5% Avoid hypoglycemia; focus on
multiple comorbidities, dementia symptom relief and safety

Terminal illness / end-of-life / Symptomatic Avoid hypoglycemia and

comfort care control only hyperglycemia symptoms;
simplify or discontinue meds

Pregnancy (T2DM) < 6.0–6.5% (if Fetal risk from hyperglycemia;

achievable safely) requires close monitoring

Post-MI / acute illness period 140–180 mg/dL Avoid tight control inpatient (↑
inpatient BG hypoglycemia risk); use insulin
drip if needed

3.4 Glycemic Parameters Beyond HbA1c

HbA1c alone does not capture the full glycemic picture. Where available, use additional parameters:

Parameter General Target Tight Control Relaxed Target

Target

HbA1c <7.0% <6.5% <8.0–8.5%

Fasting / Pre-meal 80–130 mg/dL 70–110 mg/dL 90–150 mg/dL

glucose

Post-meal (1–2 hr) <180 mg/dL <140 mg/dL <200 mg/dL

glucose

Time In Range (CGM, >70% >80% >50%

70–180)

Time Below Range <4% <4% <1%

(<70 mg/dL)

◆ CLINICAL PEARL
CLINICAL PEARL: A patient can have a 'normal' HbA1c of 7.0% while experiencing severe
hypoglycemia episodes alternating with hyperglycemia — this is glycemic variability, which
HbA1c does NOT capture. CGM (Continuous Glucose Monitoring) or structured SMBG is
essential for these patients.
★ EXAM PEARL
EXAM PEARL: In the elderly patient with T2DM, frailty, and a history of falls: the correct HbA1c
target is <8.0–8.5%. Attempting HbA1c <7% with sulfonylureas or insulin in this population
increases fall risk from hypoglycemia — a preventable cause of hip fracture and hospitalization.

When to Set a LESS INTENSIVE Target — Red Flag Checklist

• Age ≥75 years
• History of severe hypoglycemia (any unconscious episode)
• Hypoglycemia unawareness
• Multiple chronic conditions (heart failure, CKD, liver disease)
• Cognitive impairment / dementia
• Limited life expectancy (<5 years, terminal cancer, severe organ failure)
• Lives alone with no caretaker
• On complex insulin regimens with erratic meals
If ≥2 of these apply → HbA1c target <8.0% is appropriate. Consider simplifying regimen.
SECTION 4: Framework for Choosing Diabetes Medication

This section introduces the decision-making framework for pharmacologic therapy. Detailed pharmacology of
individual drug classes — including mechanisms, dosing, adverse effects, contraindications, and trial evidence —
will be covered comprehensively in Parts 2 and 3.

4.1 The 4-Step Clinical Decision Algorithm

Assess Patient Characteristics

Before selecting any medication, characterize the patient thoroughly:
STEP
• Age, BMI, renal/hepatic function, reproductive status
1 • Baseline HbA1c and severity of hyperglycemia
• Cardiovascular, renal, and complication status (from Sections 1 & 2)
• Patient priorities: weight, hypoglycemia fear, cost, injection preference

▼
Identify the Dominant Clinical Problem
Identify which clinical problem drives decision-making most urgently:
Clinical Problem Preferred Drug Class Avoid / Caution

Established ASCVD GLP-1 RA (CV benefit) —

Heart Failure SGLT2 inhibitor TZDs (fluid retention)

STEP CKD (eGFR 20–60) SGLT2i + RAAS inhibitor Metformin if eGFR <30
2 Need weight loss GLP-1 RA > SGLT2i Insulin, TZDs, SU

Hypoglycemia avoidance SGLT2i / GLP-1 RA / Sulfonylureas, insulin

DPP4i

Cost-sensitive Metformin ± Sulfonylurea ± Newer branded agents

Human insulin

Note: A patient may have multiple drivers — prioritize the highest-risk condition first.

▼
STEP Choose Medication Class Accordingly
3 Start metformin (unless contraindicated) as the foundation in most patients. Then layer
the second agent based on the dominant clinical problem identified in Step 2.
• ASCVD or high CV risk → Add GLP-1 RA with proven CV benefit
• Heart failure or CKD → Add SGLT2 inhibitor
• Weight loss needed → GLP-1 RA > SGLT2i
• Hypoglycemia avoidance critical → DPP4i or SGLT2i or GLP-1 RA
• Very high HbA1c (>10%) or symptomatic → Consider early combination or
insulin
• Cost-limited setting → Metformin + sulfonylurea + human insulin remain
 evidence-based

▼
Assess Response and Escalate Therapy
Review response at 3 months. If HbA1c target not met:
• First confirm adherence and lifestyle factors before escalating
STEP
• Add a second agent from a complementary drug class
• Consider triple therapy if dual therapy inadequate
4 • If HbA1c >10–11% with symptoms → initiate insulin early rather than stepwise
oral escalation
• Reassess comorbidities and modifying factors at every escalation step
Detailed pharmacology, drug doses, side effects, and clinical cases are covered in
Parts 2–4.

4.2 Practical Notes on the Framework

When to Bypass the Stepwise Approach and Start Combination Therapy / Insulin
Immediately
• HbA1c ≥10% at presentation → Start dual therapy or early insulin
• Symptomatic hyperglycemia (polyuria, polydipsia, weight loss) → Consider insulin initially;
can step down once stabilized
• Evidence of catabolic features (weight loss, ketonuria) → Insulin required; reassess DM
type
• Newly diagnosed T2DM in pregnancy → Metformin ± insulin immediately
• HHS or DKA at presentation → IV insulin; ensure correct DM classification before
discharge

4.3 Non-Pharmacologic Foundation — Never Omit

Drug therapy should always be combined with — not substituted for — the following:
• Medical Nutrition Therapy (MNT): Individualized by a dietitian where available; key for weight management
and postprandial glucose control
• Physical activity: ≥150 minutes moderate aerobic activity per week; resistance training 2×/week
• Weight management: In obese T2DM, >10% weight loss may induce partial remission
• Diabetes Self-Management Education (DSME): Glucose monitoring technique, sick-day rules, foot care
• Smoking cessation: Smoking doubles CVD risk and worsens insulin resistance
• Psychological support: Diabetes distress, depression, and eating disorders are common and
underdiagnosed

★ EXAM PEARL
EXAM PEARL: Lifestyle intervention alone (diet + exercise + weight loss) can normalize HbA1c
in early, mild T2DM. However, most patients will require pharmacologic therapy within 3–5 years
due to progressive beta-cell failure — the natural history of T2DM.
 ◆ CLINICAL PEARL
CLINICAL PEARL: The framework above is not linear for every patient. A 58-year-old with recent
MI, HbA1c 8.2%, eGFR 55, and obesity may correctly start on METFORMIN + SGLT2i + GLP-1
RA simultaneously at diagnosis — all three driven by different clinical mandates. Modern T2DM
management requires multi-drug, multi-benefit thinking from day one.

4.4 Summary: Drug Class Selection at a Glance

Drug Class Glycemic Weight Effect Hypoglycemia Key Use Case
Efficacy Risk

Metformin High (↓HbA1c Neutral/slight Very low First-line in most

1–2%) ↓ patients

SGLT2 Inhibitors Moderate ↓ weight Very low HF, CKD,

(↓0.5–1%) ASCVD, obesity

GLP-1 Receptor High (↓1– ↓↓ weight Very low ASCVD, obesity,

Agonists 1.5%) weight loss

DPP-4 Inhibitors Moderate Neutral Very low Elderly, renal

(↓0.5–0.8%) impairment,
hypoglycemia
avoidance

Sulfonylureas High (↓1–2%) ↑ weight High Cost-limited;

avoid in elderly

Thiazolidinediones High (↓0.8– ↑↑ weight Low NASH; avoid in

(TZDs) 1.5%) HF/osteoporosis

Basal Insulin Very High ↑ weight Moderate-High Severe

(dose- hyperglycemia;
dependent) HbA1c >10%

Detailed mechanisms, clinical trial evidence, dosing strategies, and case-based applications of each drug class
above are covered in Parts 2, 3, and 4 of this module.

END OF PART 1
Continue with PART 2 when requested
─────────────────────────────────────────────
PART 2 will cover: Pharmacology of Individual Drug Classes with Clinical Case Applications
PART 3 will cover: Complex Clinical Scenarios — Polypharmacy, Complication Management,
Intensification
PART 4 will cover: Special Populations, Monitoring, Deprescribing, and High-Yield Exam Cases